PPARδ is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-31. Numbers and descriptions here follow the published literature rather than marketing material.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
| Property | Value | Notes |
|---|---|---|
| Molecular target | PPAR delta (NR1C2) | Ligand-activated nuclear receptor. |
| Primary tissues studied | Skeletal muscle, liver, adipose | Effects on fatty acid oxidation and energy use. |
| Typical detection matrix | Urine | Used in anti-doping analysis. |
| Common analytical method | LC-MS/MS | Detects parent compound and metabolites. |
| Sport regulatory class | Prohibited at all times | Listed as a metabolic modulator by WADA. |
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is the common name for GW501516, a synthetic compound studied as a peroxisome proliferator-activated receptor delta agonist. Researchers developed it to explore treatments for lipid disorders and metabolic conditions. It is not an approved medicine in any country. Early clinical work examined changes in HDL cholesterol and triglycerides, but development was discontinued after animal studies raised concerns about cancer. The compound remains available as a research chemical and appears in discussions of performance enhancement.
At the molecular level, GW501516 binds and activates PPARδ, a nuclear receptor that regulates transcription. Activation shifts expression of genes involved in fatty acid oxidation, energy expenditure, and lipid transport in skeletal muscle and liver. Animal studies report increased endurance and altered lipid profiles after exposure. Human data are limited to small trials and do not establish long-term safety or efficacy. PPARδ also has roles in cell proliferation, so the relationship between activation and cancer risk remains an open question.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
Laboratory detection of GW501516 commonly uses liquid chromatography coupled with tandem mass spectrometry. The method can identify the parent compound or its metabolites in urine and blood after sample cleanup. Protein precipitation, solid-phase extraction, or enzymatic hydrolysis may precede analysis, depending on the matrix. Reference standards are required for accurate quantification and confirmation. Because the compound is not approved, testing often occurs in anti-doping, forensic, or research settings rather than routine clinical care. Results are reported with limits of detection and quantification.
Stability of GW501516 depends on form, temperature, light exposure, and moisture. Solid reference material is typically stored frozen or refrigerated in a desiccator and protected from light. Solutions in organic solvents such as dimethyl sulfoxide are often kept frozen in aliquots to reduce freeze-thaw cycling. Aqueous solubility is low, so aqueous stock solutions can be difficult to prepare without cosolvents. Degradation may appear as changes in chromatographic purity or mass spectral signal. Stability studies are needed to establish shelf life for any specific preparation.
1993/1359) Fresh Meat and Poultry Meat (Hygiene, Inspection and Examinations for Residues) (Charges) (Amendment) Regulations 1993 (S.I. 1993/1360) Pneumoconiosis, Byssinosis and Miscellaneous Diseases Benefit (Amendment) Scheme 1993 (S.I. 1993/1363) Combined Probation Areas (Devon) Order 1993 (S.I. 1993/1364) Barnet, Camden and Westminster (London Borough Boundaries) Order 1993 (S.I. 1993/1365) Crop Residues (Burning) Regulations 1993 (S.I. 1993/1366) Local Government Superannuation (Local Commissioners) Regulations 1993 (S.I. 1993/1367) National Health Service (Fund-Holding Practices) (Scotland) Amendment Regulations 1993 (S.I. 1993/1369) Lancashire County Council (Proposed Connecting Roads to M6 Motorway at Haighton) Special Roads Scheme 1992 Confirmation Instrument 1993 (S.I. 1993/1370) A17 Trunk Road (Leadenham Bypass) Order 1993 (S.I. 1993/1371) A17 Trunk Road (Leadenham Bypass) (Detrunking) Order 1993 (S.I. 1993/1372) King's Lynn—Newark Trunk Road (Leadenham By-pass and Slip Roads) Order 1973 (Revocation) Order 1993 (S.I. 1993/1373) Registered Restrictive Trading Agreements (Inspection, Copy and Certification) (Fees) Regulations 1993 (S.I. 1993/1376) Greater London and Surrey (County and London Borough Boundaries) (No.4) Order 1993 (S.I. 1993/1391)
Vitamin K1 is made by plants, and is found in highest amounts in green leafy vegetables, being directly involved in photosynthesis. It is active as a vitamin in animals and performs the classic functions of vitamin K, including its activity in the production of blood-clotting proteins. Animals may also convert it to vitamin K2, variant MK-4. Bacteria in the gut flora can also convert K1 into K2. All forms of K2 other than MK-4 can only be produced by bacteria, which use these during anaerobic respiration. Vitamin K3 (menadione), a synthetic form of vitamin K, was used to treat vitamin K deficiency, but because it interferes with the function of glutathione, it is no longer used in this manner in human nutrition.
== Preparation of azide == The aforementioned conversion to acyl azide has been carried out multifariously; Bergmann utilized methyl ester and hydrazide, whereas more recent attempts have designed methods such as: nitrosylation of N-formylaminoacyl hydrazide and subsequent substitution by sodium azide, reaction of a carboxylic acid with diphenyl phosphorazidate, triethylamine, and a hydroxyl component, and reaction between TMS azide and the anhydride of an amino acid.
Sources: en.wikipedia.org
== Human pathology == Accumulation of excess homogentisic acid and its oxide, named alkapton, is a result of the failure of the enzyme homogentisic acid 1,2-dioxygenase (typically due to a mutation) in the degradative pathway of tyrosine, consequently associated with alkaptonuria.
1993/1223) Value Added Tax (General) (Amendment) (No. 4) Regulations 1993 (S.I. 1993/1224) Bromley and Greenwich (London Borough Boundaries) Order 1993 (S.I. 1993/1225) Medicines (Veterinary Drugs) (Renewal Applications for Licences and Animal Test Certificates) Regulations 1993 (S.I. 1993/1227) Beer Regulations 1993 (S.I. 1993/1228) Financial Services (Designated Countries and Territories) (Overseas Insurance Companies) Order 1993 (S.I. 1993/1237) Scottish Hospital Endowments Research Trust (Amendment) Regulations 1993 (S.I. 1993/1238) National Savings Bank (Investment Deposits) (Limits) (Amendment) Order 1993 (S.I. 1993/1239) Soft Drinks (Amendment) Regulations 1993 (S.I. 1993/1240) South West Regional Flood Defence Committee Order 1993 (S.I. 1993/1241) Social Security (Widow's Benefit and Retirement Pensions) Amendment Regulations 1993 (S.I. 1993/1242) Child Abduction and Custody (Parties to Conventions) (Amendment) Order 1993 (S.I. 1993/1243) Iraq (United Nations) (Sequestration of Assets) Order 1993 (S.I. 1993/1244) Iraq (United Nations) (Sequestration of Assets) (Dependent Territories) Order 1993 (S.I. 1993/1245) Treaty on Open Skies (Privileges and Immunities) Order 1993 (S.I. 1993/1246) Treaty on Open Skies (Privileges and Immunities) (Overseas Territories) Order 1993 (S.I. 1993/1247) Turks and Caicos Islands Constitution (Amendment) Order 1993 (S.I. 1993/1248) Income-related Benefits Schemes and Social Security (Recoupment) Amendment Regulations 1993 (S.I. 1993/1249) Access to Health Records (Northern Ireland) Order 1993 (S.I.
Melarsoprol is an arsenic-containing medication used for the treatment of sleeping sickness (African trypanosomiasis). It is specifically used for second-stage disease caused by Trypanosoma brucei rhodesiense when the central nervous system is involved. For Trypanosoma brucei gambiense, eflornithine or fexinidazole is usually preferred. It is effective in about 95% of people. It is given by injection and is known by patients as "fire in the veins". Melarsoprol has a high number of side effects. Common side effects include brain dysfunction, numbness, rashes, and kidney and liver problems. About 1–5% of people die during treatment, although this is tolerated due to sleeping sickness itself having a practically 100% mortality rate when untreated. In those with glucose-6-phosphate dehydrogenase (G6PD) deficiency, red blood cell breakdown may occur. It has not been studied in pregnancy. While its mechanism of action is not fully understood, its covalent binding to trypanothione to form the toxic Mel T complex is thought to play a large role. Melarsoprol has been used medically since 1949. It is on the World Health Organization's List of Essential Medicines. In regions of the world where the disease is common, melarsoprol is provided for free by the World Health Organization. It is not commercially available in Canada or the United States. In the United States, it may be obtained from the Centers for Disease Control and Prevention, while in Canada it is available from Health Canada.
Sources: en.wikipedia.org
==== Addiction ==== Whether caffeine can result in an addictive disorder depends on how addiction is defined. Compulsive caffeine consumption under any circumstances has not been observed, and caffeine is therefore not generally considered addictive. Some diagnostic sources, such as the ICD-9 and ICD-10, include a classification of caffeine addiction under a broader diagnostic model. Caffeine does not appear to be a reinforcing stimulus, and some degree of aversion may actually occur, with people preferring placebo over caffeine in a study on drug abuse liability published in an NIDA research monograph. Some state that research does not provide support for an underlying biochemical mechanism for caffeine addiction. Other research states it can affect the reward system. "Caffeine addiction" was added to the ICD-9 and ICD-10. However, its addition was contested with claims that this diagnostic model of caffeine addiction is not supported by evidence. The American Psychiatric Association's DSM-5 does not include the diagnosis of a caffeine addiction but proposes criteria for the disorder for more study. As of 2021, the World Health Organization does not classify caffeine as an addictive substance.
Carrier females do develop mild symptoms after 2–3 months of age, but mostly do not go on to develop kidney failure. The disease is caused by a defect in the structure of the type-IV collagen fibrils of the glomerular basement membrane. As a consequence, the collagen fibrils of the glomerular basement membrane are unable to form cross-links, so the structural integrity is weakened and the membrane is more susceptible to "wear-and-tear" damage. As the structure of the basement membrane begins to degenerate, plasma proteins are lost in the urine and symptoms begin to appear. Affected males appear healthy for the first three months of life, but then symptoms start to appear and worsen as the disease progresses: the dog becomes lethargic and muscle wastage occurs, as a result of proteinuria. From three months of age onwards, a reduced glomerular filtration rate is detected, indicative of progressive kidney failure. Clinically, proteinuria is found in both sexes from the age of three to four months; in dogs older than this, kidney failure in combination with more or less pronounced hearing loss occurs swiftly and death at the age of 8 to 15 months is expected. In heterozygous females, the disease develops slowly. The disease can be treated to slow down the development by use of cyclosporine A and ACE inhibitors, but not stopped. If a carrier female is mated with a healthy stud dog, the female offspring have a 50% chance of being carriers for the disease, and any male offspring have a 50% chance of being affected by the disease. A genetic test is available for this disease.
=== Biomedical === Because one of the main purposes for biomedical engineering is to mimic body parts to sustain normal body functions, due to their biocompatible properties, biopolymers are used vastly for tissue engineering, medical devices and the pharmaceutical industry. Many biopolymers can be used for regenerative medicine, tissue engineering, drug delivery, and overall medical applications due to their mechanical properties. They provide characteristics like wound healing, and catalysis of bioactivity, and non-toxicity. Compared to synthetic polymers, which can present various disadvantages like immunogenic rejection and toxicity after degradation, many biopolymers are normally better with bodily integration as they also possess more complex structures, similar to the human body. More specifically, polypeptides like collagen and silk, are biocompatible materials that are being used in ground-breaking research, as these are inexpensive and easily attainable materials. Gelatin polymer is often used on dressing wounds where it acts as an adhesive. Scaffolds and films with gelatin allow for the scaffolds to hold drugs and other nutrients that can be used to supply to a wound for healing. As collagen is one of the more popular biopolymers used in biomedical science, here are some examples of their use: Collagen based drug delivery systems: collagen films act like a barrier membrane and are used to treat tissue infections like infected corneal tissue or liver cancer. Collagen films have all been used for gene delivery carriers which can promote bone formation.
Sources: en.wikipedia.org
It binds to and activates PPAR delta, a nuclear receptor that controls expression of genes related to fatty acid oxidation. This mechanism can alter energy metabolism in animal models. It is not a direct stimulant or fat-burning enzyme.
Early-stage trials examined lipid and glucose markers, but the development program was discontinued. Published human results are limited and do not support approved use for any indication. Claims of performance or health benefits remain unproven.
Yes. Laboratories use LC-MS/MS to detect GW501516 and its metabolites in urine. Detection depends on timing and sensitivity, but the substance is banned at all times.
Anti-doping laboratories typically use LC-MS/MS to detect GW501516 and its metabolites in urine. The method is sensitive and can identify the compound at low concentrations. Detection depends on sample timing, metabolism, and the specific assay.